Targovax announces start of patient recruitment in phase I/II study with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies
Oslo, Norway, 12 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces start of patient recruitment in phase I/II study to investigate the safety, biologic and anti-tumor activity of trial of ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies. The sponsor of the study is Ludwig Institute for Cancer Research. For further information regarding the trial, please visit ClinicalTrials.Gov